David Murray, M.D., Ph.D., provides a brief overview of the new Alpha-1-Antitrypsin Proteotype S/Z by LC-MS/MS, Serum test now available from Mayo Medical Laboratories. This test should be ordered for individuals suspected of A1A deficiency and can be used for diagnosis and identification of a specific proteotype to determine prognosis.
Clostridium difficile, an anaerobic spore-forming gram-positive bacillus, is the most important cause of antibiotic-associated diarrhea and pseudomembranous colitis. Polymerase chain reaction (PCR) assays have been developed to detect genetic markers in the PaLoc region of C difficile. While it is the most efficient direct method for laboratory diagnosis of C difficile infection, some laboratories may prefer the algorithmic approach using PCR as a confirmatory test for the presence of toxin.
Jaundice is a very common condition in newborn infants that is most often benign. However, acute and chronic bilirubin encephalopathy (acute or chronic neurologic damage resulting from high serum bilirubin levels) does still occur. Mayo Clinic used a screening algorithm to determine how to best use and interpret TcB values from healthy newborns.
In this video, Mayo Clinic gastroenterologist and celiac disease expert Joseph Murray, M.D., discusses a recent article published in Alimentary Pharmacology & Therapeutics that examined the effectiveness of larazotide acetate as an alternative treatment for celiac disease.
Mayo Clinic gastroenterologist and celiac disease expert Joseph Murray, M.D., discusses a recent article published in the Journal of Agricultural and Food Chemistry that studied the possibility that increased gluten content in wheat from wheat breeding has led to the increase of celiac disease seen during the latter part of the twentieth century.
Mayo Clinic gastroenterologist and celiac disease expert Joseph Murray, M.D., will be taking part in a webinar organized by the National Foundation for Celiac Awareness (NFCA) this Wednesday, Dec. 19, 2012. The webinar, titled “You Ask, We Answer: 60 Minutes with Top Celiac Disease Researchers,” will be an opportunity for Dr. Murray to address the gluten-free community’s most pressing questions about celiac disease. Read more to find out how to register and to learn more about Mayo Medical Laboratories’ celiac disease testing.
Melissa Snyder, Ph.D., director of the Antibody Immunology Laboratory in the Division of Clinical Biochemistry and Immunology at Mayo Clinic, discusses celiac disease testing in the October 2012 issue of CAP Today.
Clostridium difficile infections are becoming more common and more severe in hospitalized children and the elderly, in large part due to greater use of antibiotics, Mayo Clinic researchers report in studies being presented at the American College of Gastroenterology annual meeting.
Our comprehensive testing for celiac disease and inflammatory bowel disease evaluates patients suspected of having celiac disease, including patients with compatible symptoms, patients with atypical symptoms, and individuals at increased risk. We also offer a variety of interactive, step-by-step algorithms that provide the most appropriate selection of tests for each patient, while maintaining the highest possible sensitivity and specificity.
Mayo Clinic offers a test to assess for biliary tract malignancy through the combination of cytology and molecular testing by fluorescence in situ hybridization (FISH).